US welcomes Idacio and Hulio to Adalimumab biosimilars market

US welcomes Idacio and Hulio to Adalimumab biosimilars market

The US biosimilars market gains 2 more adalimumab products: Idacio by Fresenius Kabi (adalimumab-aacf) and Hulio by Biocon Biologic (adalimumab-fkjp). Both Idacio and Hulio refer to Humira (adalimumab), one of the most profitable drugs in the world. Throughout July 2023, 8 biosimilars of adalimumab are planned to be launched in the United States. The launches … Read more

Cyltezo is launched as the first interchangeable Humira biosimilar

Healio rheumatology logo

Source/Disclosures Published by: Source: Bohringer press release Disclosures: McCabe reports that he is an employee of Boehringer Ingelheim. Tesser reports financial information with AbbVie, Amgen and Boehinger Ingelheim. ADD A TOPIC TO E-MAIL ALERTS Receive an email when new articles are posted on Please provide your email address to … Read more

Cyltezo Biosimilar launches today in the United States

Cyltezo Biosimilar launches today in the United States

Boehringer Ingelheim today announced that its biosimilar adalimumab (Humira; AbbVie) Cyltezo (adalimumab-adbm) is now commercially available in the United States.1 Cyltezo is the first and only adalimumab interchangeable biosimilar approved by the US Food and Drug Administration (FDA). Cyltezo was first approved by the FDA in 2017 and received interchangeability designation in 2021. As of … Read more